Search results
Showing 1396 to 1410 of 2028 results for nice guidelines
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.
NICE has developed a medtech innovation briefing (MIB) on Proov Confirm for ovulation confirmation .
Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.
Evidence-based recommendations on endoscopic radiofrequency ablation for Barrett’s oesophagus with low-grade dysplasia or no dysplasia. This involves using radiofrequency (heat) energy to destroy the abnormal cells and promote the growth of healthy normal cells.
The clinical and cost effectiveness of proton pump inhibitors for the treatment of dyspepsia (TA7)
This guidance has been replaced by NICE guideline CG17. [Replaced by NICE guideline CG184]
Otovent nasal balloon for otitis media with effusion (MIB59)
NICE has developed a medtech innovation briefing (MIB) on the Otovent nasal balloon for otitis media with effusion
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)
Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery in adults.
NICE has developed a medtech innovation briefing (MIB) on Aptiva for painful diabetic neuropathy .
KODEX-EPD for cardiac imaging during ablation of arrhythmias (MIB260)
NICE has developed a medtech innovation briefing (MIB) on KODEX-EPD for cardiac imaging during ablation of arrhythmias .
NICE has developed a medtech innovation briefing (MIB) on Archimedes for biopsy of suspected lung cancer .
Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)
Evidence-based recommendations on fulvestrant (Faslodex), for treating locally advanced or metastatic breast cancer in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer.
Digitally enabled therapies for adults with anxiety disorders: early value assessment (HTG676)
Early value assessment (EVA) guidance on digitally enabled therapies for adults with anxiety disorders.
Upadacitinib for treating moderate rheumatoid arthritis (TA744)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderate active rheumatoid arthritis in adults.
Clarification on demonstrating patient access to medicines and treatments recommended by NICE Technology Appraisal (TA) or Highly Specialised Technologies (HST) guidance.